Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

NACompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 1, 2012

Primary Completion Date

August 31, 2020

Study Completion Date

September 30, 2020

Conditions
Liver MetastasesColon Cancer
Interventions
PROCEDURE

Dynamic contrast-enhanced ultrasound imaging

Ultrasound imaging procedure

DEVICE

Optical Tracking Device

Optical Tracking Device, manufactured by Atracsys LLC, Switzerland.

DEVICE

Electromagnetic Tracking Device

Electromagnetic Tracking Device, Ascension Technology Corporation, Milton, Vermont.

DRUG

Perflutren

Perflutren lipid microsphere, IV 0.4 mL. Used as standard contrast agent, not the subject of the study.

Trial Locations (1)

94305

Stanford University, Stanford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Philips Healthcare

INDUSTRY

lead

Stanford University

OTHER

NCT01631318 - Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases | Biotech Hunter | Biotech Hunter